| A blood RNA signature for tuberculosis disease risk: a prospective cohort study DE Zak, A Penn-Nicholson, TJ Scriba, E Thompson, S Suliman, LM Amon, ... The Lancet 387 (10035), 2312-2322, 2016 | 788 | 2016 |
| Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies S Tiberi, N du Plessis, G Walzl, MJ Vjecha, M Rao, F Ntoumi, S Mfinanga, ... The Lancet Infectious Diseases 18 (7), e183-e198, 2018 | 395 | 2018 |
| Tuberculosis: advances and challenges in development of new diagnostics and biomarkers G Walzl, R McNerney, N du Plessis, M Bates, TD McHugh, NN Chegou, ... The Lancet Infectious Diseases 18 (7), e199-e210, 2018 | 341 | 2018 |
| Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure ST Malherbe, S Shenai, K Ronacher, AG Loxton, G Dolganov, M Kriel, ... Nature medicine 22 (10), 1094-1100, 2016 | 290 | 2016 |
| Immunogenicity of Novel DosR Regulon-Encoded Candidate Antigens of Mycobacterium tuberculosis in Three High-Burden Populations in Africa GF Black, BA Thiel, MO Ota, SK Parida, R Adegbola, WH Boom, ... Clinical and Vaccine Immunology 16 (8), 1203-1212, 2009 | 193 | 2009 |
| Increased Frequency of Myeloid-derived Suppressor Cells during Active Tuberculosis and after Recent Mycobacterium tuberculosis Infection Suppresses T-Cell … N Du Plessis, L Loebenberg, M Kriel, F von Groote-Bidlingmaier, ... American journal of respiratory and critical care medicine 188 (6), 724-732, 2013 | 184 | 2013 |
| Host blood RNA signatures predict the outcome of tuberculosis treatment EG Thompson, Y Du, ST Malherbe, S Shankar, J Braun, J Valvo, ... Tuberculosis 107, 48-58, 2017 | 182 | 2017 |
| Therapeutic host-directed strategies to improve outcome in tuberculosis C Young, G Walzl, N Du Plessis Mucosal immunology 13 (2), 190-204, 2020 | 175 | 2020 |
| Asymptomatic and symptomatic excretion of noroviruses during a hospital outbreak of gastroenteritis CI Gallimore, D Cubitt, N du Plessis, JJ Gray Journal of clinical microbiology 42 (5), 2271-2274, 2004 | 166 | 2004 |
| Monocytic myeloid-derived suppressor cells in chronic infections A Dorhoi, N Du Plessis Frontiers in immunology 8, 1895, 2018 | 148 | 2018 |
| Metabolite changes in blood predict the onset of tuberculosis J Weiner 3rd, J Maertzdorf, JS Sutherland, FJ Duffy, E Thompson, ... Nature communications 9 (1), 5208, 2018 | 142 | 2018 |
| S100A8/A9 regulates CD11b expression and neutrophil recruitment during chronic tuberculosis NR Scott, RV Swanson, N Al-Hammadi, R Domingo-Gonzalez, ... The Journal of clinical investigation 130 (6), 3098-3112, 2020 | 118 | 2020 |
| RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response A Penn-Nicholson, SK Mbandi, E Thompson, SC Mendelsohn, S Suliman, ... Scientific reports 10 (1), 8629, 2020 | 118 | 2020 |
| Short-term reproducibility of a commercial interferon gamma release assay AK Detjen, L Loebenberg, HMS Grewal, K Stanley, A Gutschmidt, ... Clinical and Vaccine Immunology 16 (8), 1170-1175, 2009 | 97 | 2009 |
| Differential gene expression of activating Fcγ receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity JS Sutherland, AG Loxton, MC Haks, D Kassa, L Ambrose, JS Lee, L Ran, ... Clinical microbiology and infection 20 (4), O230-O238, 2014 | 86 | 2014 |
| The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty? OA Eribo, N du Plessis, M Ozturk, R Guler, G Walzl, NN Chegou Cellular and Molecular Life Sciences 77, 1497-1509, 2020 | 75 | 2020 |
| Analysis of Host Responses to Mycobacterium tuberculosis Antigens in a Multi-Site Study of Subjects with Different TB and HIV Infection States in Sub-Saharan Africa JS Sutherland, MK Lalor, GF Black, LR Ambrose, AG Loxton, NN Chegou, ... PloS one 8 (9), e74080, 2013 | 68 | 2013 |
| Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa JA Shaw, M Meiring, T Cummins, NN Chegou, C Claassen, N Du Plessis, ... Plos one 16 (2), e0247852, 2021 | 66 | 2021 |
| Safety and immunogenicity of the adjunct therapeutic vaccine ID93+ GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo … TA Day, A Penn-Nicholson, AKK Luabeya, A Fiore-Gartland, N Du Plessis, ... The Lancet Respiratory Medicine 9 (4), 373-386, 2021 | 62 | 2021 |
| The emerging role of myeloid-derived suppressor cells in tuberculosis T Magcwebeba, A Dorhoi, N du Plessis Frontiers in immunology 10, 917, 2019 | 53 | 2019 |
